<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00348387</url>
  </required_header>
  <id_info>
    <org_study_id>IPV13</org_study_id>
    <nct_id>NCT00348387</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of Imovax Polio in Chinese Infants Compared to Local OPV</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended to support the registration of IMOVAX Polio in China.&#xD;
&#xD;
      The primary objective of this Pase III trial is to compare IMOVAX Polio to the current&#xD;
      Chinese standard of care (OPV) that is administered following a schedule of 2-3-4 months. The&#xD;
      objective is to demonstrate that after the 3 doses primary series, in terms of seroprotection&#xD;
      rates, IMOVAX Polio is not inferior to OPV. The safety of IPV will be assessed after each IPV&#xD;
      dose.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To provide information concerning the immunogenicity of IMOVAX Polio™ vaccine</measure>
    <time_frame>1 month post-vaccination 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To provide information concerning the safety of IMOVAX Polio™ vaccine</measure>
    <time_frame>Entire study period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">600</enrollment>
  <condition>Poliomyelitis</condition>
  <condition>Polio</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Poliomyelitis Vaccine inactivated</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>IMOVAX Polio ™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Poliomyelitis Vaccine in Dragee Candy (Human Diploid Cell)</intervention_name>
    <description>1g dragee, oral</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Poliomyelitis Vaccine in Dragee Candy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 2 months (60-70 days) on the day of inclusion into the study&#xD;
&#xD;
          -  Born at full term pregnancy ( over 36 weeks) with a birth weight ≥ 2.5 kg 2Ibs) or&#xD;
             more&#xD;
&#xD;
          -  Parent(s) or legal representative able to understand and give authorization and sign&#xD;
             informed consent for participation&#xD;
&#xD;
          -  Able to attend all planned clinic appointment and obey and follow all study&#xD;
             instructions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Taking part in another clinical trial during the 4 weeks before the first trial&#xD;
             vaccination&#xD;
&#xD;
          -  Have plans to take part in another clinical trial d during this trial period&#xD;
&#xD;
          -  Inborn or acquired decreased body natural defense, undertaking treatment that can&#xD;
             reduce body's natural defense such as cancer drugs, radiation in the past six months&#xD;
             or long term corticosteroid treatment&#xD;
&#xD;
          -  Systemic reaction to any vaccine component or history of life-threatening reaction to&#xD;
             study vaccine or any vaccine with the same ingredient(s)&#xD;
&#xD;
          -  Prolonged or long time illness that could interfere with study or full participation&#xD;
&#xD;
          -  Received blood or blood-derived products since birth&#xD;
&#xD;
          -  Received any vaccine in the 4 weeks before the first trial vaccination is given&#xD;
             (except BCG and hepatitis B)&#xD;
&#xD;
          -  Have plans to receive any vaccine in the 4 weeks after the (or any) study vaccination&#xD;
             is given (except DTacP)&#xD;
&#xD;
          -  Previous vaccination against the poliomyelitis infection with the trial vaccine or&#xD;
             another vaccine&#xD;
&#xD;
          -  History of poliomyelitis infection (confirmed either by symptoms, blood or other&#xD;
             laboratory test)&#xD;
&#xD;
          -  Clinical or serological evidence of systemic illness including hepatitis B, hepatitis&#xD;
             C or Human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Bleeding disorder or a low platelet which do not allow vaccination into the muscle&#xD;
&#xD;
          -  Had seizures in the past&#xD;
&#xD;
          -  Febrile illness (axillary temperature ≥ 37.1°C) or acute illness on the day of&#xD;
             inclusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Days</minimum_age>
    <maximum_age>70 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Guilin City,</city>
        <zip>541001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>PingLe county</city>
        <zip>542400</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>July 3, 2006</study_first_submitted>
  <study_first_submitted_qc>July 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2006</study_first_posted>
  <last_update_submitted>January 20, 2014</last_update_submitted>
  <last_update_submitted_qc>January 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Imovax polio</keyword>
  <keyword>poliomyelitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Poliomyelitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

